NTLA Q4 2018 Earnings — Intellia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

NTLAIntellia Therapeutics, Inc.

$2B

Q4 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$8M+18.2% YoY

Gross Profit

-$12M-152.8% margin

Operating Income

-$21M-263.3% margin

Net Income

-$19M-242.0% margin

EPS (Diluted)

$-0.43

QoQ Revenue Growth

+6.4%

Cash Flow

Operating Cash Flow

-$9M

Free Cash Flow

-$10M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$347M

Total Liabilities

$69M

Stockholders' Equity

$278M

Cash & Equivalents

$59M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$8M	$7M	+18.2%
Gross Profit	-$12M	-$15M	+17.0%
Operating Income	-$21M	-$25M	+16.1%
Net Income	-$19M	-$24M	+20.4%